Survival of cystic fibrosis patients undergoing liver and liver-lung transplantations

Transplant Proc. Jan-Feb 2013;45(1):290-2. doi: 10.1016/j.transproceed.2012.02.033. Epub 2012 Sep 13.

Abstract

Background: We evaluated the outcome of combined liver-lung transplantation (L-LTx) in cystic fibrosis (CF) patients with liver transplantation (LTx) for CF liver disease.

Methods: The United Network for Organ Sharing (UNOS) data were analyzed from October 1987 to August 2009.

Results: Of 294 patients (210 children), 265 (90.1%) received an LTx and 29, an L-LTx. Patient survival was: adult LTx, 80%, 74%, and 67% at 1, 3, and 5 years, and L-LTx, 72%, 61.4%, and 61.4% (P = .7); pediatric LTx, 85%, 82%, and 74% at 1, 3, and 5 years, and L-LTx, 83%, 83%, and 83% (P = .4). Pediatric patients had a slight survival advantage over adults for LTx (P = .08). Graft survival, not affected by immunosuppression regimens, was similar to patient survival.

Conclusions: The outcome of L-LTx appears similar to LTx in CF providing support for the prospect of a combined transplant.

MeSH terms

  • Adolescent
  • Adult
  • Cystic Fibrosis / mortality*
  • Cystic Fibrosis / therapy*
  • Databases, Factual
  • Female
  • Graft Survival
  • Humans
  • Liver Cirrhosis, Biliary / complications
  • Liver Cirrhosis, Biliary / therapy
  • Liver Transplantation / methods*
  • Lung Transplantation / methods*
  • Male
  • Time Factors
  • Treatment Outcome
  • Young Adult